PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.

Saved in:
Bibliographic Details
Main Authors UNOKI, Gen, MINAMIZONO, Kunio, MIZUNO, Tsuyoshi, HORIE, Kyohei, MARUYAMA, Akinobu, TAKAHASHI, Hiroshi, SHIMADA, Tomohiro, YOKOSAKA, Takuya, EBISAWA, Masaru, TAKEUCHI, Susumu, SAKAI, Yuri, SASAKI, Kosuke, IGARASHI, Junji
Format Patent
LanguageEnglish
French
German
Published 11.04.2018
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

Abstract The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.
AbstractList The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.
Author IGARASHI, Junji
SAKAI, Yuri
HORIE, Kyohei
SHIMADA, Tomohiro
EBISAWA, Masaru
SASAKI, Kosuke
TAKAHASHI, Hiroshi
MIZUNO, Tsuyoshi
MINAMIZONO, Kunio
YOKOSAKA, Takuya
UNOKI, Gen
TAKEUCHI, Susumu
MARUYAMA, Akinobu
Author_xml – fullname: UNOKI, Gen
– fullname: MINAMIZONO, Kunio
– fullname: MIZUNO, Tsuyoshi
– fullname: HORIE, Kyohei
– fullname: MARUYAMA, Akinobu
– fullname: TAKAHASHI, Hiroshi
– fullname: SHIMADA, Tomohiro
– fullname: YOKOSAKA, Takuya
– fullname: EBISAWA, Masaru
– fullname: TAKEUCHI, Susumu
– fullname: SAKAI, Yuri
– fullname: SASAKI, Kosuke
– fullname: IGARASHI, Junji
BookMark eNrjYmDJy89L5WTwD4gM8nTxjzbWMdFNiQVxfD1dPP1cFVxcgzzDHEM8w1wVHP1cFAI8HIN8HZ1dQ0M8nR19fCIVHJ2dXQNCHJ18XBWCHX1CFEI8XINc_d14GFjTEnOKU3mhNDeDgptriLOHbmpBfnxqcUFicmpeakm8a4CxsYGpuYWpo6ExEUoAR7wweg
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate DÉRIVÉ DE PYRIDO[3,4-d]PYRIMIDINE ET SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI
PYRIDO[3,4-D]PYRIMIDIN-DERIVAT UND PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON
ExternalDocumentID EP3305785A1
GroupedDBID EVB
ID FETCH-epo_espacenet_EP3305785A13
IEDL.DBID EVB
IngestDate Fri Jul 19 12:48:45 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
German
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_EP3305785A13
Notes Application Number: EP20160803266
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180411&DB=EPODOC&CC=EP&NR=3305785A1
ParticipantIDs epo_espacenet_EP3305785A1
PublicationCentury 2000
PublicationDate 20180411
PublicationDateYYYYMMDD 2018-04-11
PublicationDate_xml – month: 04
  year: 2018
  text: 20180411
  day: 11
PublicationDecade 2010
PublicationYear 2018
RelatedCompanies Teijin Pharma Limited
RelatedCompanies_xml – name: Teijin Pharma Limited
Score 3.141882
Snippet The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180411&DB=EPODOC&locale=&CC=EP&NR=3305785A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS8MwFA5jivqmU3HeyIP0yeLS6_YwJEtSWlkv1GxsiIxeYS_dcBX_vknZpi_6dpJASA58Sb6cnC8APAysrDfop4lqlshSjVJ-5K6XSNX0zLJKW7PKQt53-IHlToyXmTlrgeUuF6bRCf1qxBEFojKB97pZr9c_l1i0eVu5eUqXomr17PAhVbbsGEk1HaTQ0ZBFIQ2JQoiwlCAeCtouZV2wIEoH4hRtSzCw6Ugmpax_7yjOKTiMRGdVfQZaRdUBx2T38VoHHPnbeLcwt9DbnIMwmsceDd_0R0PN32XB96gXMEgFFZti7k0ZxAGFkYtjHxM24VLpYDyHmBAWcTwaM_iKxxxyl8UsdC4AdBgnripGtth7YcGi_Rz0S9CuVlVxBaCZmVna09K-0dcMsxD8BWW5ndq60UuSJE-6oPtnN9f_tN2AE-lOGTdB6Ba064_P4k5sv3V63zjuGzEpgvc
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS8MwFA5jivNNp-K85kH6ZHG9bw9DsiSl1d6o2diQMdquhb10w1X8-yZlm77o20kCITnwJflycr4A8NA3s26_lyayUSimrBfiI3etUGRVy0yzsFSzyMV9hx-Yzkh_mRiTBljucmFqndCvWhyRIyrjeK_q9Xr9c4lF6reVm6d0yatWzzYbEGnLjhWhpqNIZDigUUhCLGHMLSmIB5y2C1kXxInSAT9hWwIMdDwUSSnr3zuKfQIOI95ZWZ2CRl62QQvvPl5rgyN_G-_m5hZ6mzMQRtPYJeG79qjLi5ko-C5xAwoJp2JjxNwxhSggMHJQ7CNMR0woHXhTiDCmEUNDj8I35DHIHBrT0D4H0KYMOzIf2XzvhTmN9nPQLkCzXJX5JYBGZmRpV017ek_VjZzzFyVbWKml6d0kSRZJB3T-7Obqn7Z70HKY7809N3i9BsfCtSKGoig3oFl9fOa3fCuu0rvaid-BmoXq
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=PYRIDO%5B3%2C4-d%5DPYRIMIDINE+DERIVATIVE+AND+PHARMACEUTICALLY+ACCEPTABLE+SALT+THEREOF&rft.inventor=UNOKI%2C+Gen&rft.inventor=MINAMIZONO%2C+Kunio&rft.inventor=MIZUNO%2C+Tsuyoshi&rft.inventor=HORIE%2C+Kyohei&rft.inventor=MARUYAMA%2C+Akinobu&rft.inventor=TAKAHASHI%2C+Hiroshi&rft.inventor=SHIMADA%2C+Tomohiro&rft.inventor=YOKOSAKA%2C+Takuya&rft.inventor=EBISAWA%2C+Masaru&rft.inventor=TAKEUCHI%2C+Susumu&rft.inventor=SAKAI%2C+Yuri&rft.inventor=SASAKI%2C+Kosuke&rft.inventor=IGARASHI%2C+Junji&rft.date=2018-04-11&rft.externalDBID=A1&rft.externalDocID=EP3305785A1